Expanding TAVI to Low and Intermediate Risk Patients

TAVI has become the standard treatment in patients at increased surgical risk and is increasingly being performed in patients at intermediate to low surgical risk. While non-inferiority has been demonstrated in intermediate risk patients, several challenges—particularly with regard to valve durabili...

Descripción completa

Detalles Bibliográficos
Autores principales: Voigtländer, Lisa, Seiffert, Moritz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052659/
https://www.ncbi.nlm.nih.gov/pubmed/30050909
http://dx.doi.org/10.3389/fcvm.2018.00092
_version_ 1783340702903566336
author Voigtländer, Lisa
Seiffert, Moritz
author_facet Voigtländer, Lisa
Seiffert, Moritz
author_sort Voigtländer, Lisa
collection PubMed
description TAVI has become the standard treatment in patients at increased surgical risk and is increasingly being performed in patients at intermediate to low surgical risk. While non-inferiority has been demonstrated in intermediate risk patients, several challenges—particularly with regard to valve durability—need to be addressed before expansion to lower risk and younger patients can be recommended on a broad basis. Current trends, trials results, and remaining challenges are summarized and discussed in the light of updated treatment guidelines.
format Online
Article
Text
id pubmed-6052659
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60526592018-07-26 Expanding TAVI to Low and Intermediate Risk Patients Voigtländer, Lisa Seiffert, Moritz Front Cardiovasc Med Cardiovascular Medicine TAVI has become the standard treatment in patients at increased surgical risk and is increasingly being performed in patients at intermediate to low surgical risk. While non-inferiority has been demonstrated in intermediate risk patients, several challenges—particularly with regard to valve durability—need to be addressed before expansion to lower risk and younger patients can be recommended on a broad basis. Current trends, trials results, and remaining challenges are summarized and discussed in the light of updated treatment guidelines. Frontiers Media S.A. 2018-07-12 /pmc/articles/PMC6052659/ /pubmed/30050909 http://dx.doi.org/10.3389/fcvm.2018.00092 Text en Copyright © 2018 Voigtländer and Seiffert. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Voigtländer, Lisa
Seiffert, Moritz
Expanding TAVI to Low and Intermediate Risk Patients
title Expanding TAVI to Low and Intermediate Risk Patients
title_full Expanding TAVI to Low and Intermediate Risk Patients
title_fullStr Expanding TAVI to Low and Intermediate Risk Patients
title_full_unstemmed Expanding TAVI to Low and Intermediate Risk Patients
title_short Expanding TAVI to Low and Intermediate Risk Patients
title_sort expanding tavi to low and intermediate risk patients
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052659/
https://www.ncbi.nlm.nih.gov/pubmed/30050909
http://dx.doi.org/10.3389/fcvm.2018.00092
work_keys_str_mv AT voigtlanderlisa expandingtavitolowandintermediateriskpatients
AT seiffertmoritz expandingtavitolowandintermediateriskpatients

Ejemplares similares